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OBJECTIVES: To assess preference and willingness-to-
pay (WTP) for the insulin mixture Humalog Mix25 rel-
ative to Humulin 30/70, from the perspective of patients
in ﬁve European countries. The relative value of indi-
vidual treatment attributes was also determined.
METHODS: A total of 290 patients with type 2 diabetes
were enrolled from 5 European countries. Of these, 235
were suitable for inclusion in the analysis. Their mean age
was 51.3 years and, on average, patients had had diabetes
for 11 years. A discrete-choice conjoint analysis was con-
ducted using face-to-face interviews. Treatment attributes
and levels were derived from published comparative clin-
ical trial data available at July 2001. The attributes used
were: timing of injections around meals; two-hour post-
prandial control; effect of prandial dosing; frequency of
nocturnal hypoglycaemia; and cost. RESULTS: 90%
(95% CI 86–93%) of patients would choose Humalog
Mix25 over Humulin 30/70, at the same cost. On
average, European subjects were willing to pay €111 
per month more for Humalog Mix25 (95% CI
€86.71–156.91). The primary driver was the reduced risk
of nocturnal hypoglycaemic events, contributing 49% of
WTP. The convenience of dosing immediately prior to the
meal contributed 37% and improved postprandial blood
glucose concentrations contributed 14% to the WTP.
Preference results were similar in all ﬁve countries,
although WTP and sensitivity to increasing cost varied
from country to country. The WTP values for individual
countries were: France €146.83; Germany €126.65; Italy
€56.98; Spain €150.06; United Kingdom €194.36. French
and UK patients were relatively insensitive to increasing
cost, while Italian patients were highly cost-sensitive.
CONCLUSIONS: Patients in all countries showed a clear
preference for Humalog Mix 25 over Humulin 30/70.
WTP ﬁgures for the individual countries can be compared
with the corresponding additional acquisition costs for
Humalog Mix25, relative to Humulin 30/70, to assess the





THE EQUITY-EFFICIENCY TRADEOFF:WHAT IS
THE SOCIAL INTERPRETATION OF EQUITY?
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OBJECTIVES: There is increasing awareness that equity
weights should be used to recalculate the value of QALY
gains for different patients. It is unclear however how
these equity weights should be determined: on the basis
of health prospects (for instance “rule of rescue”), fair
innings, or on a combination of both, for instance an
equity concept that has been referred to as proportional
shortfall. To answer this question, we compared the
observed rank order of 10 conditions with the theoreti-
cal rank orders that were predicted by each equity
concept. METHODS: 60 respondents (students, re-
searchers, health policy makers) rank ordered 10 condi-
tions using the paired comparison technique. This
observed rank order was compared to the rank orders
expected on the basis of the equity concepts fair innings,
prospective health and proportional shortfall. To allow
for comparison of the conditions in terms of each equity
concept, we described the conditions in terms of age,
disease free period, duration of disease, quality of life, and
life years lost. RESULTS: The observed rank order of the
10 conditions was best predicted by the fair innings
concept (corr. = 0.908, p < 0.01). Proportional shortfall
was also well correlated with the observed rank order of
the conditions (corr. = 0.780, p < 0.01), but prospective
health was not statistically signiﬁcantly related. This is
remarkable, as it has often been suggested that the “rule
of rescue” is the most important determinant of the dis-
tribution of health care. CONCLUSIONS: Measurable
interpretations of equity make it possible to test the
importance of concepts of equity in the allocation of
health care. The fair innings argument and proportional
shortfall may provide a basis for determining equity
weights for recalculating the value of QALY gains for dif-
ferent patients. When put to a critical test, the prospec-
tive health argument is out weighted by arguments
resembling fair innings.
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OBJECTIVES: To evaluate the feasibility and validity of
daily self-reported performance in relation to objective
productivity data, in order to develop measures of health
effects on work function. METHODS: Medical bill
reviewers at 3 worksites of the same ﬁrm provided daily
information through interactive voice response (IVR) on
speed, concentration and accuracy compared to their 
best on a 1–10 ordinal scale for 12 weeks. The 7-item
Work Limitations Questionnaire (WLQ) was adminis-
tered monthly. Objective data included types of bills
processed and speciﬁc processing activities. Weights for
relative difﬁculty of activity were applied, and outliers
were removed. RESULTS: One hundred and twenty four
of 142 recruited subjects (87%) completed > 50% of daily
IVR reports. Concentration, speed and accuracy ratings
were highly inter-correlated (R = 0.75), and right-skewed
(mean speed = 7.7, SD = 1.5). The mean adjusted pro-
ductivity rate (MAP) was 34 bills/hour (range 4.7 to 111,
SD12.6, 61% within-person variation). Subject-speciﬁc
speed/MAP correlation ranged from R = -.20 to .75
(mean, .28). Health status, years on job, age, IVR com-
pletion rate, month of study, or total hours worked were
not associated with variations across individuals in R.
Correlations among WLQ responses, IVR speed, and
monthly objective productivity were low (R < 0.12).
CONCLUSIONS: Daily subjective and objective data col-
lection are feasible; both may be equally valid, in the sense
that they may be measuring different aspects of work per-
formance. Even with a relatively well-deﬁned job and
limited range of tasks, the “objective” data was complex
and challenging to analyze. Low subjective/objective cor-
relations may be due to respondent inability to relate 
productivity to the IVR questions or monthly survey
items; subjects incorporating difﬁculty adjustment in their
ratings and/or failure of “objective” data to capture the
full complexity of the job or difﬁculty variation.
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OBJECTIVE: Disease models are of increasing interest
and inﬂuence on decision support, outcomes research and
health technology assessment in Europe. Validity and reli-
ability of the incorporated medical evidence in arithme-
tical modeling software is crucial for the simulated
outcomes. Currently the diabetes modeling software
Accusim®TM, ﬁrst established in 1996, is being validated
for the 2002 edition. METHODS: Input validity: The
Australian MERGE checklist system is used for the liter-
ature assessment in order to assess the level of evidence
and the likelihood of bias. Process validity: The model is
based on Markov processes and has been published
several times in peer-review journals. Outcome validity:
The model was run against published population based
diabetes data and is under constant review by indepen-
dent medical experts. Currently an advisory board is
being established. RESULTS: When calculating the
expected life expectancy for representative type-2 dia-
betes patients aged 65 years against published American
diabetes data the computed life expectancy of the model
is 12.1 years versus 12.3 years published (2% deviation).
The accuracy of simulated life expectancy decreases in
younger patients with computed 17.4 years versus pub-
lished 18.9 years in 55 year-old patients (8% deviation).
From the literature screening, out of a total of 3512 
literature references, 1007 were eligible for structured
assessment, only 85 references (2.4% of all) were eligible
for being used for the modeling software. CONCLU-
SION: Validation is a labour intensive and continuous
process. Methods of evidence-based medicine are needed
for supporting the development and validation of disease
models. Yet only few references meet the quality criteria
for disease modeling. Disease models are able to compute
reliable results in realistic scenarios. Disease modeling is
important for outcomes research, monitoring and evalu-
ation of disease management programmes, as well as for
risk stratiﬁcation and health technology assessment.
HEALTHCARE POLICY STUDIES
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OBJECTIVES: To examine the relationship between pub-
lished cost-effectiveness data and the adoption of health
technologies into routine practice in the UK and to assess
trends in the types of study being published. METHODS:
An electronic literature search identiﬁed incremental cost-
effectiveness ratios (ICERs) of health interventions pub-
lished between 1997 and 2001. Studies were classiﬁed 
by intervention type and disease category and compared
with previous UK and US reviews. The technologies were
ranked by standardised ICERs and the number falling
within the £20–30,000 range considered cost-effective by
the National Institute for Clinical Excellence (NICE) was
estimated. For two sub-samples, the highest ICERs and
those for non-pharmaceutical technologies, the degree of
adoption was estimated using activity statistics, clinical
guidelines and policy documents. RESULTS: The 84 new
studies included a larger proportion of pharmaceutical
interventions (57%) then an earlier published UK analy-
sis (37%) and a US league table (31%). The distribution
of the ICERs in the UK league tables was not statistically
different (Mann-Whitney for independent samples p =
0.316), but the overall median ICER grew over time:
£5,000 vs £6,500, varying in different disease categories,
